Parkinson’s disease patients may soon find hope in a groundbreaking pilot study conducted at Be Well Hospital in Chennai, India. Researchers discovered that Nichi-BRITE Beta glucans, a food supplement derived from the AFO-202 strain of Aureobasidium Pullulans, led to marked improvements in patients’ Unified Parkinson’s Disease Rating Scale (UPDRS) and constipation scores after 90 days of oral administration.
The relationship between gut health and neurological conditions like Parkinson’s disease is increasingly being recognized as crucial in understanding and treating these disorders. Nichi-BRITE Beta glucans have the potential to control harmful gut bacteria while promoting the growth of beneficial microbiota, making them a promising candidate for further research.
Dr. Dedeepiya, a co-author of the study, was optimistic about Nichi-BRITE’s potential as an adjunct therapy for synucleinopathies, such as Parkinson’s disease and multiple system atrophy. Dr. Nithyanandam, the study’s neurologist, underscored the importance of conducting larger, more extensive studies to better understand Nichi-BRITE’s capabilities.
During a World Parkinson’s Day webinar, Prof. Muralidhar Hegde from Houston Methodist Research, USA, discussed the role of alpha-synuclein abnormalities in the onset of neurodegenerative diseases. Dr. Rukmini Mridula from Hyderabad shed light on the increasing number of young-onset Parkinson’s disease cases in India.
With the encouraging results from this pilot study, Nichi-BRITE Beta glucans could soon become a key weapon in the battle against Parkinson’s disease, offering a brighter future for millions of patients worldwide.